key: cord-0734222-mjbdif44
authors: Mpekoulis, George; Frakolaki, Efseveia; Taka, Styliani; Ioannidis, Anastasios; Vassiliou, Alice G.; Kalliampakou, Katerina I.; Patas, Kostas; Karakasiliotis, Ioannis; Aidinis, Vassilis; Chatzipanagiotou, Stylianos; Angelakis, Emmanouil; Vassilacopoulou, Dido; Vassilaki, Niki
title: Alteration of L-Dopa decarboxylase expression in SARS-CoV-2 infection and its association with the interferon-inducible ACE2 isoform
date: 2021-06-29
journal: PLoS One
DOI: 10.1371/journal.pone.0253458
sha: 965e195caed9a521c725798faa61073ae3b9f11b
doc_id: 734222
cord_uid: mjbdif44

L-Dopa decarboxylase (DDC) is the most significantly co-expressed gene with ACE2, which encodes for the SARS-CoV-2 receptor angiotensin-converting enzyme 2 and the interferon-inducible truncated isoform dACE2. Our group previously showed the importance of DDC in viral infections. We hereby aimed to investigate DDC expression in COVID-19 patients and cultured SARS-CoV-2-infected cells, also in association with ACE2 and dACE2. We concurrently evaluated the expression of the viral infection- and interferon-stimulated gene ISG56 and the immune-modulatory, hypoxia-regulated gene EPO. Viral load and mRNA levels of DDC, ACE2, dACE2, ISG56 and EPO were quantified by RT-qPCR in nasopharyngeal swab samples from COVID-19 patients, showing no or mild symptoms, and from non-infected individuals. Samples from influenza-infected patients were analyzed in comparison. SARS-CoV-2-mediated effects in host gene expression were validated in cultured virus-permissive epithelial cells. We found substantially higher gene expression of DDC in COVID-19 patients (7.6-fold; p = 1.2e-13) but not in influenza-infected ones, compared to non-infected subjects. dACE2 was more elevated (2.9-fold; p = 1.02e-16) than ACE2 (1.7-fold; p = 0.0005) in SARS-CoV-2-infected individuals. ISG56 (2.5-fold; p = 3.01e-6) and EPO (2.6-fold; p = 2.1e-13) were also increased. Detected differences were not attributed to enrichment of specific cell populations in nasopharyngeal tissue. While SARS-CoV-2 virus load was positively associated with ACE2 expression (r≥0.8, p<0.001), it negatively correlated with DDC, dACE2 (r≤−0.7, p<0.001) and EPO (r≤−0.5, p<0.05). Moreover, a statistically significant correlation between DDC and dACE2 expression was observed in nasopharyngeal swab and whole blood samples of both COVID-19 and non-infected individuals (r≥0.7). In VeroE6 cells, SARS-CoV-2 negatively affected DDC, ACE2, dACE2 and EPO mRNA levels, and induced cell death, while ISG56 was enhanced at early hours post-infection. Thus, the regulation of DDC, dACE2 and EPO expression in the SARS-CoV-2-infected nasopharyngeal tissue is possibly related with an orchestrated antiviral response of the infected host as the virus suppresses these genes to favor its propagation.

a1111111111 a1111111111 a1111111111 a1111111111 a1111111111

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, singlestranded RNA virus, which leads to coronavirus disease 2019 . The mechanisms underlying virus-host interaction remain largely unknown. Symptoms range from fever, dry cough and dyspnea to the development of acute pneumonia, while neurological manifestations (loss of smell and taste, consciousness impairment, parkinsonism) have been also reported [1] . Severe aggravation in some patients has been associated with dysregulation of the immune response and induction of an inflammatory storm [2] . SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor [3] . Apart from the full-length ACE2, an N-terminally truncated isoform, termed deltaACE2 (dACE2), has been recently reported, as a result of initiation from an alternative first exon, which is conserved only in primates [4, 5] . In contrast to ACE2, dACE2 protein does not bind the viral spike protein and dACE2 is an interferon-stimulated gene (ISG), induced after SARS-CoV-2 infection. dACE2 shows high expression in airway epithelial cells, in contrast to the lower levels of ACE2. The ratio of expression of the dACE2 to ACE2 is highest in nose and mouth and reduces in the lower respiratory tract. Although a transcriptome analysis of nasopharyngeal samples showed ACE2 induction in COVID-19 patients [6] , it has been hypothesized, but not experimentally addressed, that this is due to dACE2 and not ACE2 [4] .

Analysis of a large number of human microarray datasets from various tissues revealed that the L-Dopa decarboxylase (DDC) gene exhibited the most statistically significant co-expression link with ACE2 locus [7] . DDC catalyzes decarboxylation reactions, among them the conversion of L-3,4-dihydroxyphenylalanine (L-Dopa) to the immune-modulatory catecholamine dopamine [8, 9] and of 5-hydroxytryptophan to the inflammation and immunity regulator serotonin [10] . Both dopamine and serotonin act also as neurotransmitters providing a linkage between immune and neuron systems [11] . A physiological role for DDC in cell proliferation and apoptosis has been shown [12, 13] . In addition, our group was the first to unravel that DDC expression is associated with viral infections, and specifically has a negative relationship with hepatitis C (HCV) and Dengue (DENV) virus proliferation, in non-neuronal cells and in liver biopsies of HCV-infected patients [14] . Currently, there are no studies addressing the association of DDC expression with SARS-CoV-2 infection. However, viral proteins have been shown to interact with the catecholamine degradation enzymes monoamine oxidase A (MAOA) and catechol-O-methyltransferase (COMT) [15] , and COMT has been reported as necessary for SARS-CoV-2 infection [16] . These findings, and the necessity of investigating the virus-host interactions for the emerging SARS-CoV-2, prompted us to extend our study on DDC in COVID-19 patients.

Both DDC and ACE2 are regulated by hypoxia through mechanisms dependent on hypoxia-inducible factors (HIFs), as observed in various cell types, including airway epithelial cells [14, [17] [18] [19] [20] [21] [22] . In nasal epithelial cells, HIF has been implicated in immunity and inflammation [23] and its target gene EPO has been regarded as a hypoxia marker [24] . However, prolonged hypoxia in cultured alveolar epithelial cells (A549) has been shown to induce apoptosis [25] and destabilizes HIF-1α mRNA, thus reducing the expression of its target genes [26] . SARS--CoV-2 infection results in airway and lung hypoxia that contributes to COVID-19 inflammation [27] . Cell culture data derived from alveolar and bronchial epithelial cells have revealed that although some of the HIF-α targets, such as VEGF, are upregulated by SARS-CoV-2, VHL that targets HIF-α to degradation is also upregulated [28] . In turn, HIF-1α activation inhibits SARS-CoV-2 infection in the these cells [22] , at least in part due to lower ACE2 expression and subsequent reduction of cell attachment of the viral spike protein [29] . In serum, lower levels of EPO have been detected in COVID-19 critical and deceased patient groups than in healthy ones [30] .

In this study, we investigated the expression of DDC, ACE2 and its interferon-inducible isoform dACE2 in COVID-19 patients and in cultured SARS-CoV-2-infected cells. In parallel, the expression of other anti-viral host cell response related genes, specifically the viral infection-and interferon-inducible gene ISG56 and the immune-modulatory, hypoxia-regulated gene EPO was also analyzed. A group of influenza-infected patients was studied in comparison, to examine if the detected alterations in gene expression are specific to COVID-19. Specifically, in nasopharyngeal swab samples from infected and non-infected subjects, we studied whether DDC, ACE2, dACE2, ISG56 and EPO mRNA levels are associated with SARS-CoV-2 infection and viral RNA amounts. Moreover, the correlations among the mRNA levels of these genes were evaluated in nasopharyngeal swab and whole blood samples of COVID-19 patients. Finally, we determined in cultured mammalian epithelial cells (VeroE6, A549) the effects on gene expression exerted by SARS-CoV-2 virus and by hypoxia, a condition that has been associated with SARS-CoV-2 infection in airway epithelium.

We tested a series of nasopharyngeal swab samples collected from patients with COVID-19 and from non-infected individuals as control. The inclusion criteria for patients were male or female adults having positive SARS-CoV-2 RNA PCR and showing no or mild COVID-19 clinical symptoms, including cough, sore throat, mild fever below 38˚C and loss of smell. The control group included individuals with a negative SARS-CoV-2 RNA PCR. For comparison, nasopharyngeal swab samples from patients infected with influenza A or B were also tested. All samples were received from outpatients in Greece.

This study was based on routine diagnosis samples from the biobank of Eginition Hospital (Athens, Greece). All collected data were anonymized in standardized forms. Written informed consent was obtained from all individuals. For the minors, consent was obtained from parents or guardians. The study was conducted in accordance with the ethical standards noted in the 1964 Declaration of Helsinki and its later amendments. The study, which is part of DopaHypoCov-SARSCoV2 2020 Institut Pasteur International Network program, has been approved by the Administration Board of the Hellenic Pasteur Institute.

Nasopharyngeal swab specimens were collected in 2 ml of viral nucleic acid sample preservation fluid. Total RNA extraction was performed with the MagNA Pure LC Total Nucleic Acid Isolation Kit using the MagNa Pure LC 2.0 automated nucleic acid purifier (Roche), as recommended by the manufacturer. cDNA synthesis for cellular genes was performed using the Moloney murine leukemia virus reverse transcriptase (Promega) according to the manufacturer's protocol, oligo d(T)18 primer (New England Biolabs) and the recombinant ribonuclease inhibitor (Takara). After reverse transcription (RT), real-time quantitative PCR (qPCR) was performed in cDNA reactions using the SYBR Green-based Luna 1 Universal qPCR Master Mix (New England Biolabs) as well as primer pairs specific for DDC, ACE2, dACE2, ISG56 and EPO (Table 1) , previously validated [5, 12, [31] [32] [33] , or the cell type marker genes EPCAM, CD45, CD74 and LYN (S1 Table) . The primers for DDC bind to exons 10 and 12, and detect the majority of the known DDC mRNA isoforms [8, 34] . The house-keeping gene 14-3-3-zeta polypeptide (YWHAZ) was used as a normalization control. We routinely included negative and positive controls in each assay, and the quality of RNA extraction was verified for all samples.

VeroE6 and A549 epithelial cell lines were cultured in Dulbecco's modified minimal essential medium (DMEM) (Invitrogen), supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin and 10% (v/v) fetal calf serum, at 37˚C, 5% CO 2 . To create 3% (v/v) oxygen tension, cells were cultured in a fully humidified incubator supplied with pure nitrogen gas to reduce oxygen as well as with 5% (v/v) CO 2 at 37˚C (New Brunswick CO 2 incubator Innova). SARS-CoV-2 (isolate 30-287, lineage B1), derived from a positively testing oropharyngeal swab Table 1 . Priming oligonucleotides used for RT-qPCR analysis.

Orientation

Reverse GGCTGCAGAAAGTGACATGA dACE2

Forward GTGAGAGCCTTAGGTTGGATTC [5] Reverse TAAGGATCCTCCCTCCTTTGT ISG56

Forward GGACAGGAAGCTGAAGGAG [33] Reverse AGTGGGTGTTTCCTGCAA EPO Forward GCCCCACCACGCCTCATCTGT [31] sample of a COVID-19 patient in Alexandroupolis (Greece) [35] , was propagated in VeroE6 cells. Fully confluent cells were infected and four days after inoculation, the supernatant was collected and stored at −80˚C for further usage. Titration was carried-out in VeroE6 cells seeded in 96-well plates that were cultured at 37˚C for 4 days, and the cytopathic effect (CPE) was monitored using inverted phase contract microscopy. TCID 50 was determined based on the method of Reed and Muench [36] .

Infections of VeroE6 cells with SARS -CoV-2 (m.o.i. of 0.1) were carried out in 6-well plates. Mock-treated cells were cultured in parallel, as control. At 24 and 48 hours post-infection, cells were lysed using NucleoZOL (Macherey-Nagel) and cell lysates were analyzed using RT-qPCR.

ATP was measured using the ViaLight HS BioAssay Kit (Lonza), according to the manufacturer's protocol, in a GloMax 20/20 single tube luminometer (Promega) for 1 s. ATP levels were normalized to total protein amount.

The relative quantification method 2 −ΔΔCt [37] was used to normalize the gene expression data with respect to the reference gene and obtain fold change values of positive and negative groups, using the respective gene expression values of control samples as a calibrator. Based on the Kolmogorov-Smirnov (KS) test, we verified if data distribution was parametric or nonparametric and subsequently selected the appropriate statistical test for analysis. Comparison of gene expression between positive and control group samples was performed using the student's t-test (unpaired). We evaluated the diagnostic accuracy of gene expression with the receiver operating characteristic (ROC) regression analysis and calculated for each gene the area under the ROC curve (AUC), as well as the cut-off value based on Youden's index. Correlations between the mRNA levels of the genes and with the viral RNA were determined by Pearson's or Spearman's correlation coefficient (r), for parametric and non-parametric data, respectively. We estimated the statistical relationship between gene expression and demographic data by Pearson's r for age (continuous variables) and by either the parametric student's t-test or the non-parametric Mann-Whitney U test for sex (binary variable). All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, Inc.) and p<0.05 (two-tailed) was considered statistically significant.

We tested nasopharyngeal swab samples from 37 COVID-19 patients showing no or mild COVID-19 clinical symptoms, including cough, sore throat, mild fever below 38˚C and loss of smell, and 38 non-infected individuals ( Table 2 ). The median age of COVID-19 patients was 38 years (interquartile range-IQR = 31-52), and the negative control group had median age 47 years (IQR = 34-68). In comparison, nasopharyngeal swab samples from 38 patients infected with influenza A or B were also tested, and their demographic data are shown on S2 Table.

DDC mRNA expression. In nasopharyngeal swab samples, a significant increase in DDC mRNA expression with 7.6 mean-fold (p = 1.2e-13) was observed in SARS-CoV-2 patients (median = 0.035; IQR = 0.016-0.047), as compared to non-infected subjects (median = 0.004; IQR = 0.003-0.006) ( Fig 1A) . Moreover, the ROC curve analysis revealed high ability of DDC to distinguish between infected and non-infected individuals ( Fig 1B) , with an area under the curve (AUC) of 0.98 (95% confidence interval-CI = 0.95-1.003). At the optimal cut-off value of 0.007, the sensitivity and specificity were 95% and 90%, respectively. Finally, we found that DDC mRNA levels were higher in men as compared to women, for both positive (1.8-fold of mean; p = 0.02) and negative (1.5-fold of mean; p = 0.007) groups (Fig 2) . No correlation with age was observed (S1 Fig in S2 File).

ACE2 and dACE2 mRNA expression. The mRNA levels of the ISG dACE2 were higher by 2.9 mean-fold (p = 1.02e-16) in COVID-19 patients (median = 0.021; IQR = 0.017-0.031) compared to the non-infected individuals (median = 0.008; IQR = 0.006-0.01) ( Fig 1A) . A lower increase of 1.7 mean-fold was detected for the viral receptor-encoding ACE2 gene in the positive (median = 0.007; IQR = 0.004-0.011) versus the negative (median = 0.004; IQR = 0.003-0.007) group ( Fig 1A) . ROC curve analysis determined for dACE2 a much higher AUC of 0.97 (95% CI = 0.92-1.01) than for ACE2 (AUC = 0.7; 95% CI = 0.58-0.82) (Fig 1B) . In addition, the cut-off point value for dACE2 was calculated at 0.012, with a sensitivity of 92% and a specificity of 100%. No correlation was observed with sex ( S2 Fig in S2 File) or age (S1 Fig in S2 File) for ACE2 and dACE2.

ISG56 and EPO mRNA expression. As dACE2 is considered an ISG [4] , we comparatively evaluated the expression of the well-studied ISG56 gene. Similar to dACE2, SARS-CoV-2-infected patients had 2.5 mean-fold higher (p = 3.012e-6) ISG56 mRNA levels (median = 1.194; IQR = 0.572-2.106), as compared to the non-infected subjects (median = 0.521; IQR = 0.358-0.814) (Fig 1A) . However, the discriminating accuracy determined for ISG56 (AUC = 0.76; 95% CI = 0.64-0.88) (Fig 1B) was lower than dACE2, with a sensitivity of 57% and a specificity of 100% at the cut-off point from the ROC (0.987). 

Since DDC and ACE2 expression is regulated by hypoxia [14, [17] [18] [19] [20] 22] and the HIF-target immune-modulatory gene EPO [21] , we concurrently examined the expression profile of EPO in COVID-19 patients compared to the non-infected individuals. EPO mRNA levels were higher by a mean-fold of 2.6 (p = 2.1e-13) in SARS-CoV-2 patients (median = 0.024; IQR = 0.017-0.034), as compared to the control group (median = 0.01; IQR = 0.007-0.013) ( Fig 1A) . Moreover, a high discriminating accuracy was determined for EPO (AUC = 0.96; 95% CI = 0.92-1.0) (Fig 1B) . At the cut-off point from the ROC (0.014), EPO showed a sensitivity of 100% and a specificity of 82%.

We sought to exclude the possibility that the detected alterations of DDC and dACE2 expression in SARS-CoV-2 infected patients might be due to enrichment of specific inflammationrelated cell populations expressing these genes in nasopharyngeal tissue. For this, we compared gene expression of the epithelial cell marker EPCAM and immune cell markers CD45, CD74 and LYN (for macrophages, neutrophils, dendritic, natural killer, B and T lymphocytes) between COVID-19 positive and negative sample subsets representing the entire range of DDC and dACE2 expression (Fig 3A) . Both epithelial ( Fig 3B) and immune ( Fig 3C) cell markers had no significant differences between the two groups, possibly because the COVID-19 samples are derived from patients with only mild or no symptoms. To validate the primers used in the analysis, we compared the expression of these markers in airway epithelial A549 and monocytic THP-1 cell lines (S3 Fig in S2 File) .

Next, the specific cell types expressing DDC in the SARS-CoV-2-infected nasopharyngeal tissue were determined by analyzing the gene expression data of the previously reported single-cell RNA-Sequencing study [6] that are available in Magellan COVID-19 data explorer (https://digital.bihealth.org). According to the dataset derived from 14 nasopharyngeal swab To elucidate if DDC expression is altered specifically in SARS-CoV-2 infection or also in other respiratory viral infections, influenza-positive swab samples were analyzed in comparison to the COVID-19 and infection-negative ones presented above. In contrast to COVID-19, DDC mRNA levels in the influenza-positive samples were not significantly different than the ones in the negative control group (Fig 4A) . For dACE2, a slightly higher expression by 1.8 mean-fold (p = 0.0125) was shown in influenza-positive (median = 0.008; IQR = 0.004-0.010) versus negative samples (Fig 4B) , which is however lower than the one observed in the SARS--CoV-2 group (2.9 mean-fold). 

Because the expression of DDC and ACE2/dACE2 genes was significantly higher in SARS--CoV-2 infected patients, we further assessed the relationship between the respective gene mRNA levels and viral load, as measured by the detection of the viral RNA levels. Interestingly, while viral RNA amounts were positively associated with ACE2 expression (Pearson's r �0.8, p <0.001), they had a strong negative correlation (r �−0.7, p <0.001) with DDC and dACE2 mRNA levels (Fig 5A-5C) , with similar results for both E and RdRp regions. Moreover, viral RNA had no correlation with ISG56 and a moderate negative correlation with EPO expression (r �−0.5, p <0.05) (Fig 5D and 5E ).

Next, we examined the association of mRNA expression among the genes studied in COVID-19 patients and non-infected subjects. In the virus-infected group, we observed a strong correlation between DDC and dACE2 mRNA levels (Pearson's r = 0.74, p = 1.3e-07, Fig 6A) , while a less robust correlation (r = 0.45, p = 0.004, Fig 6A) was identified in the non-infected group. However, no such correlation was found between the expression of ACE2 and that of DDC or dACE2 (Fig 6B and 6C ). In addition, moderate correlations were observed between the expression of EPO with that of DDC (r = 0.62, p = 4.6e-05, Fig 7A) or dACE2 (r = 0.64, p = 2.5e-05, Fig 7B) in the virus-infected individuals. The non-infected group presented significant but less robust correlations of dACE2 with EPO mRNA levels (r = 0.44, p = 0.006, Fig 7B) and no correlation of DDC with EPO (p = 0.36, Fig 7A) . No correlation was shown between the expression of EPO with that of ACE2 ( Fig 7C) and of ISG56 with DDC or with ACE2/dACE2 (Fig 7D and  7E, S5 Fig in S2 File) . These results suggested that a statistically significant correlation between 

As the expression of DDC and dACE2 was negatively correlated with the viral load in SARS--CoV2 infected patients, we aimed to directly verify if the virus downregulates these genes in the target epithelial cells. For this, VeroE6 cells were infected with a SARS-CoV-2 strain of lineage B1 for 24 or 48 hours. Upon viral infection, there was a substantial reduction in the mRNA levels of DDC (2-fold) and dACE2 (3.5-and 7-fold, at 24 h and 48 h post-infection, respectively), as well as in the ACE2 mRNA levels (6.3-and 17.5-fold at the two time points tested) (Fig 8) . A different kinetics was noticed for ISG56 mRNA, which showed an about 2-fold increase at 24 h post-infection but afterwards was suppressed by 1.7-fold. Similar to DDC and dACE2, the virus negatively affected EPO expression by about 5-fold. On the other hand, expression analysis of another hypoxia marker gene GLUT1 showed an upregulation at 24 h post-infection. In accordance to these results in VeroE6, processing of data acquired from the RNA-sequencing Skyline database (http://rstats.immgen.org/Skyline_COVID-19/skyline. html) [38] revealed that SARS-CoV-2 infection reduced the expression of DDC also in A549, A549 overexpressing ACE2 and Calu3 cell lines ( S7A Fig in S2 File) and that of EPO in A549 (S7B Fig in S2 File) , whereas increased other hypoxia markers, such as GLUT1 and VEGFA (S7C and S7D Fig in S2 File) .

The upregulation of GLUT1 and VEGFA in SARS-CoV-2-infected cells suggest the activation of a hypoxia-associated signaling upon viral infection. On the other hand, the negative effect in EPO expression may be exerted by the virus in an attempt to reduce the IFN-related [39, 40] immune-modulatory function of erythropoietin [41] . Another reason for SARS-CoV-2 to target EPO could be the anti-apoptotic properties [42] of the encoded protein, as the virus induces cell death in VeroE6, shown in S8 Fig in S2 File [35] and also in previous studies [43, 44] . To investigate the possibility that the virus-mediated effects on the expression of the genes under study in cell culture are related to hypoxia and/or cell viability, we analyzed their expression in airway epithelial cells under low oxygen tension as well as in a number of conditions that promote or not cell death. To simulate the effect of hypoxia in A549 cells, we cultured them under 3% O 2 for 48 hours compared to atmospheric O 2 levels (20% O 2 ) that these cells physiologically sense in vivo. The expression of GLUT1 gene was analyzed as a marker of hypoxia. As shown in Fig 9A, GLUT1 expression was found increased at 3% O 2 in A549, verifying that these cells had activated the hypoxia-related cellular response. DDC, dACE2, EPO and ISG56 expression was significantly reduced at 3% O 2 , whereas no effect was exerted by hypoxia on ACE2 expression. This downregulation coincided well with a hypoxia-mediated 25% reduction in cell viability of A549 (Fig 9B) . These results are in agreement with previous data showing that prolonged hypoxia (�12 h) triggers apoptosis in these cells [45] and destabilizes HIF-1α mRNA, causing a reduction in the expression of its target genes (e.g. EPO), in contrast to HIF-2α that is increased in both acute and prolonged hypoxia and regulates GLUT1 and VEGFA [26] . In contrast to A549 cells, hepatic epithelial cells (Huh7.5) showed increased EPO expression after long exposure to 3% O 2 (S9A Fig in S2 File) , a condition previously shown to positively affect the viability of these cells [46] .

To further explore the link of the reduction in DDC, dACE2 and EPO expression with virus-induced cell death, we comparatively employed the infection models of DENV and HCV at late hours post-infection. DENV promotes cell death [47] , as does SARS-CoV2, whereas HCV does not affect cell viability of Huh7.5 cells [46] . As shown in S9B and S9C Fig in S2 File, DENV reduced the expression of EPO, similar to SARS-CoV2 (Fig 8) , while no effect was exerted by HCV at the late time-point tested. In addition to EPO, DDC [14] and dACE2 were also suppressed by DENV, but dACE2 was not suppressed by HCV. On the other hand, both viruses positively affected the expression of ACE2, which is in accordance with previous data supporting ACE2 upregulation upon DENV infection [48] and a negative correlation between the expression of ACE2 and many interferon-stimulated genes [49] . 

Our results showed that the gene expression of DDC (L-Dopa decarboxylase) [8] and of the recently reported interferon-inducible truncated dACE2 isoform [4, 5] was significantly higher in nasopharyngeal swab samples from COVID-19 patients with no or mild symptoms, as compared to non-infected individuals, while it was negatively correlated with SARS-CoV-2 RNA levels in patients and was negatively affected by the virus in cell culture-infected epithelial cells. A similar pattern of expression to DDC and dACE2 was also observed for the hypoxiaregulated immune-modulatory gene EPO, in SARS-CoV-2-infected individuals and cultured cells. The detected differences in gene expression in the COVID-19 nasopharyngeal samples were not resulted from an enrichment of specific cell populations in this tissue, as there was no significant difference in the expression of epithelial and immune cell marker genes between SARS-CoV-2 positive and negative samples. DDC expression did not differ between influenzapositive and negative swab samples, underlining the specific relation of DDC regulation with SARS-CoV-2 infection. Moreover, the negative correlation between the mRNA levels of DDC, dACE2 and EPO with viral load in SARS-CoV-2 positive samples combined with their downregulation in infected VeroE6 cells, that mount an inefficient innate response [50, 51] , suggest that SARS-CoV-2 genome replication and virus spread occurs in parallel with the suppression of these genes. Based on the above, we assume that the expression reprogramming of DDC, dACE2 and EPO in COVID-19 patients, as compared to non-infected individuals, possibly constitute an antiviral immune strategy of the infected host. Alternatively, SARS-CoV-2 might benefit from the lower levels of expression of these genes in certain individuals to achieve efficient propagation. On the other hand, the viral receptor encoding mRNA ACE2 exhibited a lower increase in SARS-CoV-2 positive samples and a similar expression pattern in VeroE6 infected cells as compared to dACE2, whereas its expression levels positively correlated with the viral load in patients. This possibly suggests that the increased expression of ACE2 in certain individuals makes them vulnerable to SARS-CoV-2 infection resulting in high virus titers. A positive effect from SARS-CoV-2 on ACE2 is less possible, as the virus was shown to downregulate ACE2 in our in vitro studies. A similar increase to dACE2, was also observed for another interferon-stimulated gene, ISG56, in COVID-19 patients but no correlation was shown with viral load. Furthermore, we revealed a significant correlation in the expression levels of DDC and dACE2, whereas no correlation was found with ACE2 in nasopharyngeal swab and blood samples of both SARS-CoV-2-infected and non-infected individuals.

Concerning DDC, this is the first report on the involvement of an enzyme gene belonging to the catecholamine/serotonin synthesis pathway in SARS-CoV-2 infection. Processing of the single cell gene expression data (RNA-sequencing) of Chua et al. [6] derived from nasopharyngeal swabs of COVID-19 patients revealed that DDC is almost exclusively expressed in epithelial cells (secretory, ciliated and FOXN4) and not in immune cell populations. This is in agreement with the absence of an effect on DDC expression in other viral diseases causing inflammation of the respiratory tract, such as influenza A or B, and as mentioned above, this underlines the specific association of SARS-CoV-2 infection with DDC regulation. Our in vitro results showing the downregulation of DDC after SARS-CoV-2 infection of VeroE6 cells are consistent with other in vitro data in A549 and Calu3 lung epithelial cells (S7 Fig in S2 File [38] ). Interestingly, to our knowledge SARS-CoV-2 is the third virus found to cause DDC downregulation [14] . In relation to the present finding of DDC and SARS-CoV2 negative association in the nasopharyngeal swabs, our previous data have shown the negative correlation of DDC mRNA levels with HCV RNA in patient liver samples, and the downregulation of DDC mRNA and protein by HCV and DENV replication in cultured cells of non-neuronal origin [14] . A negative relationship between SARS-CoV-2 and this pathway is further supported by a study showing that the catecholamine degradation enzyme COMT is required for SARS-CoV-2 infection [16] . Moreover, interactome and proteome analyses revealed the association of the viral proteins ORF7b, NSP4, NSP7 and M with COMT, as well as of ORF7b with the catecholamine-catabolizing enzyme MAOA [15, 52] . Effects caused by DDC expression and DDCactivity related products on SARS-CoV-2 proliferation are also possible, as our previous experiments have shown that HCV and DENV RNA replication was reduced upon DDC overexpression and treatment with dopamine or serotonin, while it was favored upon DDC inhibition [14] . In addition, activation of serotonin receptor signaling by agonist 5-nonyloxytryptamine has been found to diminish infectivity of the coronavirus mouse hepatitis virus, the reovirus and the alphavirus chikungunya [53] . According to the Chinese academy of science, series of tryptamine derivatives have anti-viral activity against hepatitis B virus replication [54] . In turn, yellow fever and Coxsackie B4 viral infections impair persistently the synthesis of catecholamines (dopamine, noradrenaline) in infant mice [55] . The reduction of DDC expression by SARS-CoV2, which results in hampered biosynthesis of the neurotransmitters dopamine and serotonin, provides insight in the cause of the neurological manifestations frequently observed in these patients. In line with this, previous data on the crucial role of DDC-dependent synthesis of serotonin in taste bud cells for normal taste functions [56] might explain the high incidence of smell and/or taste loss in patients [57] . Moreover, serotonin has been shown to exert functions in innate as well as adaptive immunity, [58] thus a putative SARS-CoV-2-mediated deregulation of its production may be extremely beneficial for the virus.

An upregulation in SARS-CoV-2-infected patients, as compared to the control group, and a negative correlation with viral RNA levels was also observed for dACE2 transcript. Our data on the expression pattern of dACE2 in the nasopharyngeal tissue and in in vitro studies in VeroE6 cells are possibly explained by the reported function of dACE2 as an ISG [4, 5] and the suppression of interferon signaling by SARS-CoV-2 [38] , combined with the insufficient production of IFNs in response to viral infection in VeroE6 [50, 51] . Indeed, Onabajo O. et al. have previously shown that dACE2 is not inducible by IFNs in VeroE6 [4] . As SARS-CoV-2 is known to be highly potent in inhibiting IFN expression and signaling from the type I IFN receptor, compared to other respiratory viruses [39, 40] , similar to our data, in infected cultures of bronchial epithelial cells no significant induction of IFN-stimulated genes has been observed [4] . Similar to SARS-CoV-2, another RNA virus that efficiently inhibits IFN response, DENV [59] , also reduces both dACE2 and DDC. Based on single cell RNA-seq analyses (further analysis of Chua et al. data that are available in https://digital.bihealth.org; and [60] ), the common chromosomal locus of ACE2/dACE2 was found to be transcribed in epithelial cell subpopulations of the nasal airway tissue, where innate immune genes are highly expressed [60] . Thus, combined our findings on dACE2 and ACE2 support the recently reported hypothesis that the 3-fold higher ACE2 levels shown in a transcriptome analysis of nasopharyngeal COVID-19 patient samples, compared to the control group [6] , are due to dACE2 and not ACE2 [4] .

A similar increase to dACE2, we also detected for another interferon-stimulated gene, ISG56, in COVID-19 patients as compared to the non-infected individuals, in agreement with the study of Scagnolari C. et al. on oropharyngeal swabs [61] , as well as an in vitro transient, slight upregulation early after SARS-CoV2 infection and subsequent decrease. However, in contrast to dACE2, no correlation was shown in patients between ISG56 mRNA levels and viral load, which implies that these two ISGs are subjected to different regulation mechanisms during viral infection.

Compared to dACE2 and ISG56, EPO exhibited a similar induction in response to SARS--CoV-2 infection in patients but had a moderate negative correlation with viral load. In cell culture, EPO expression was reduced in SARS-CoV-2 infected VeroE6 cells, consistently with the RNA-seq data of Blanco-Melo et al. in A549 cells (S7 Fig in S2 File; [38] ), in contrast to other hypoxia markers (GLUT1, VEGFA) that were increased upon viral infection. The later indicates that SARS-CoV-2 triggers a hypoxia-like response in infected cells. On the other hand, the SARS-CoV-2 infection-mediated effect on EPO, in VeroE6 cells, is possibly related with the induction of cell death. Indeed, EPO expression was reduced in hypoxic A549 cells, in agreement with previous reports showing that long exposure to hypoxia (�12 h) triggers apoptosis in A549 [45] and destabilizes HIF-1α mRNA, causing a reduction in the expression of its target genes (e.g. EPO), but not in HIF-2α targets (GLUT1 and VEGFA) [26] . EPO was also suppressed by the apoptotic virus DENV in hepatic epithelial cells, but not after hypoxia treatment, a condition that increases viability of these cells [46] . Overall these results are in line with the proposed use of human recombinant EPO in severe COVID-19 cases as beneficial for the alleviation of respiratory inflammation [62] . Furthermore, our experiment in A549 cells showed that hypoxia is a condition that downregulates all three genes DDC, dACE2 and EPO, whereas has no impact on ACE2 expression, suggesting that hypoxia signaling in these cells may constitute a possible mechanism of co-regulation of the three genes during SARS-CoV-2 infection.

Finally, we showed that the statistically significant expression correlation of DDC with dACE2 and of both DDC and dACE2 with EPO in nasopharyngeal tissue was higher in SARS--CoV-2-infected as compared to the non-infected individuals, while no correlation with the expression of the viral receptor gene ACE2 was found. These data complements previous ones on the co-expression of DDC with total ACE2 in epithelial cells of other tissues [7] and on the regulation of DDC gene expression by HIF [14, 17] and EPO [21] . DDC, dACE2 and EPO mRNA levels correlated well also in whole blood of SARS-CoV-2-infected as well of noninfected individuals. This tissue is a significant source of RNAs derived from vesicles and ribonucleoproteins secreted from different cells and tissues of the body [63] .

This study, combining data derived from COVID-19 patients and cultured SARS-CoV2-infected cells, provides new knowledge on the involvement of the dopamine biosynthetic enzyme gene DDC in SARS-CoV-2 infection and its association with dACE2 expression, which could lead to further understanding of COVID-19 pathogenesis. Our results support that, DDC and dACE2 are upregulated in patients with mild or no symptoms as a response to SARS-CoV-2 infection, while there is a negative association between their expression and viral RNA levels and in vitro the virus acts to suppress their expression. Thus, their reprogramming is possibly related with an antiviral response of the infected individuals, as the virus downregulates these genes to favor its propagation. Moreover, the finding that the mRNA levels of DDC and dACE2 correlate well between them in COVID-19 nasopharyngeal and whole blood samples, but not with the viral receptor encoding isoform ACE2, complements and extends previous studies on the co-expression link of DDC with ACE2 locus in epithelial cells of other tissues. Finally, we presented data showing that, in airway epithelial cells, SARS-CoV-2 infection triggers a hypoxia-like condition, and interestingly hypoxia reduces cell viability and suppresses DDC, dACE2 and the HIF-target gene EPO in these cells. Further investigation is needed to address the involvement of these genes in disease severity.

Supporting information S1 

World Health Organization: Coronavirus disease (COVID-19)

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor

A novel isoform of ACE2 is expressed in human nasal and bronchial respiratory epithelia and is upregulated in response to RNA respiratory virus infection

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19

DDC (dopa decarboxylase (aromatic L-amino acid decarboxylase))

Immunomodulatory Effects Mediated by Dopamine

Neurotransmitters of the Brain: Serotonin Noradrenaline (Norepinephrine), and Dopamine

L-Dopa decarboxylase interaction with the major signaling regulator PI3K in tissues and cells of neural and peripheral origin

Human L-Dopa decarboxylase interaction with annexin V and expression during apoptosis

Emerging Role of l-Dopa Decarboxylase in Flaviviridae Virus Infections

Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms

Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors

Hypoxia inducible factor (HIF)-2 alpha is required for the development of the catecholaminergic phenotype of sympathoadrenal cells

Hypoxic regulation of angiotensin-converting enzyme 2 and Mas receptor in human CD34(+) cells

Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress

Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells

Gamma-Aminobutyric Acid Increases Erythropoietin by Activation of Citrate Cycle and Stimulation of Hypoxia-Inducible Factors Expression in Rats

Hypoxic and Pharmacological Activation of HIF Inhibits SARS-CoV-2 Infection of Lung Epithelial Cells

The role of hypoxia inducible factor in nasal inflammations

Hypoxia effects on vascular endothelial growth factor derived epithelial cells of nasal polyps

Hypoxia-inducible transcription factor-1alpha promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway

Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha

A key feature of COVID-19 launching activation of HIF-1 and cytokine storm

Host metabolic reprogramming in response to SARS-Cov-2 infection

Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2 and heparan sulfate

The relationship between serum erythropoietin, hepcidin, and haptoglobin levels with disease severity and other biochemical values in patients with COVID-19

Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro

ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia

Hepatitis C virus reveals a novel early control in acute immune response

Identification of novel alternative splice variants of the human L-DOPA decarboxylase (DDC) gene in human cancer cells, using high-throughput sequencing approaches

A mixture of essential oils from three Cretan Aromatic Plants (thyme, Greek sage and Cretan dittany, CAPeo) inhibits SASR-CoV-2 proliferation: in vitro evidence and a Proof-of-Concept intervention study in mild ambulatory COVID-19-positive patients

A Simple Method of Estimating Fifty Per Cent Endpoints12

Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

Dysregulation of type I interferon responses in COVID-19

The pleiotropic effects of erythropoietin in infection and inflammation

Erythropoietin as an antiapoptotic, tissue-protective cytokine

SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation

Apoptosis induced by SARS-CoV-2: can we target it?

Role of Hypoxia-Inducible Factor-1α in Hypoxia-Induced Apoptosis of Primary Alveolar Epithelial Type II Cells

Low oxygen tension enhances hepatitis C virus replication

The Role of Tissue Oxygen Tension in Dengue Virus Replication. Cells

Contact System Activation in Plasma from Dengue Patients Might Harness Endothelial Virus Replication through the Signaling of Bradykinin Receptors

Negative regulation of ACE2 by interferons in vivo and its genetic control. Infectious Diseases (except HIV/AIDS)

Regulation of the Interferon System: Evidence that Vero Cells have a Genetic Defect in Interferon Production

New World Hantaviruses Activate IFNλ Production in Type I IFN-Deficient Vero E6 Cells

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Serotonin Receptor Agonist 5-Nonyloxytryptamine Alters the Kinetics of Reovirus Cell Entry

Tryptamine derivatives as novel nonnucleosidic inhibitors against hepatitis B virus

Virus infections in infant mice causing persistent impairment of turnover of brain catecholamines

Mammalian Taste Bud Cells Utilize Extragemmal 5-Hydroxy-L-Tryptophan to

Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients

The Effects of Serotonin in Immune Cells

Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19)

Erythropoietin as candidate for supportive treatment of severe COVID-19

Variety of RNAs in Peripheral Blood Cells, Plasma, and Plasma Fractions

This manuscript is dedicated to the memory of our dear collague and co-author Efseveia Frakolaki, who passed away while the manuscript was under revision.